AIM BREAKFAST – 18th September 2016
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 994
Total number of AIM Companies trading: 975*
* As at 17 October 2016
Dish of the Day:
No AIM Primary Today
No AIM Primary Today
Off the Menu:
Sable Mining Africa’s (SBLM.L) delisted from AIM yesterday Premier Farnell (PFL.L) leaves the main market today following a cash offer
Sable Mining Africa’s (SBLM.L) delisted from AIM yesterday
Premier Farnell (PFL.L) leaves the main market today following a cash offer
Set Menu ISDX Growth:
Total number of ISDX Growth Market Companies (Incl Susp): *
Total number of ISDX Growth Market Companies trading: *
* As at 17 October 2016
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Misys— Press reports that the IPO valuation is to be cut by £1bn against an expected £5bn
TI Van Elle—The geotechnical contractor to the UK construction market is hoping to come to AIM later this month
Ascot Lloyd— The UK IFA is also hoping to join AIM later this month. Ascot Lloyd’s strategy is to grow through a combination of organic growth and further targeted acquisitions.
Directa Plus (DCTA.L) 121p £53.5m
The producer and supplier of graphene-based products for use in consumer and industrial markets, announced that Ufficio Brevetti e Marchi (Italian Patent and Trademark Office) has issued notification that a further two patents have been granted covering Directa Plus’ proprietary G+ manufacturing process. The Company now has a portfolio of 14 patents granted and eight pending.
Clinigen Group (CLIN.L) 750p £860m
The global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen KK further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen KK will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from Nobel Pharma on 1 November 2016. FY Jun16E EPS of 41.18p and 4.75p dividend.
Accesso Technology (ACSO.L) 1620p £360m
The technology solutions provider to leisure, entertainment and cultural markets, today announces a three year agreement with Village Roadshow Theme Parks to install the accesso LoQueue virtual queuing solution at Wet’n’Wild Sydney. The agreement will see accesso’s patented Qbandsm deployed across nine attractions in one of Australia’s most visited water parks. FYDec2016E revenues of £77.4m and EPS of 34.24p.
Digital Barriers (DGB.L) 46.5p £76.79m
The specialist provider of visually intelligent solutions to the global surveillance, security and safety markets has agreed a two year £10m revolving credit facility with Investec Bank plc. The funds available through the facility will be used to meet the increasing working capital requirements of the Group’s organic growth, helping to ensure that the Group’s stock levels are better able to keep track with contracted revenue growth. FYMAR17E revenues of £43.7p and pre tax profit of 0.5p rising to £48.2m and £2.9m for FY18E.
Orogen Gold (ORE.L) 0.02p £1.33m
The gold exploration company, reports on its review of the recent diamond drilling programme and further planned step-out drilling at the Mutsk gold project in southern Armenia. Management strongly encouraged by preliminary modelling of 2016 drill results. Potential for significant strike additions. Step-out holes planned to north and south. Immediate drilling start-up. The additional drilling is expected to be completed in approximately 4-5 weeks.
Tethyan Resources (TETH.L) 2.25 p £2.03m
Tethyan has announced an exploration update for the Suva Ruda project over which it has an option and its proprietary Gokcanica copper-gold project both located in Central Serbia. A sampling programme has defined a coincident copper and molybdenum anomaly in soils over a 1200 meter by up to 600 meter area, with a maximum molybdenum sample value of 59 ppm. Molybdenum is a good indicator for porphyry mineralisation as it is not generally mobile in the weathering environment. 2500m drill programme to start imminently.
Botswana Diamonds (BOD.L) 1.6p £5.4m
Further to the notification of 9 September 2016, drilling has commenced on kimberlite pipe AK 22 on Licence PL 260 in the Orapa area of Botswana. A further announcement will be made as soon as practicable regarding the commencement of drilling on licence PL 135 in the Gope region.
88 Energy (88E.L) 2.82p £110m
The Company has provided an update on Project Icewine, located onshore North Slope of Alaska (77.5% working interest). Interpretation of modern 2D seismic data acquired by 88 Energy in early 2016 has identified multiple large conventional leads in Brookian Sequence across the Project Icewine acreage. 758 million barrels of prospective mean recoverable oil (gross) identified in current top 5 leads. 88E will undertake further technical work in order to mature the evolving conventional portfolio from which future likely drilling candidates will be selected.
Hardide (HDD.L) 0.95p £14.58m
The provider of advanced surface coating technology, announced a pre-close trading update ahead of the publication of its preliminary results for the year ending 30 September 2016. The Company expects to report preliminary year-end results that are in line with current market expectations with H2 seeing an improvement over H1, as projected at the time of the interim results. There are signs of a slow recovery from oil and gas markets, both from existing customers and from new opportunities. Positive progress in aerospace.
Marshall Motor Hldgs (MMH.L) 137p £106.3m
The top 10 UK motor dealer with 103 franchises has noted the recent (downwards) movement in its share price. Other than general speculation surrounding the potential impact of Brexit on the UK economy and the automotive sector in particular, the Board knows of no reason for this. Reiterated that the outlook for the full year remains in line with previous expectations. Specifically, that FYDec16E should represent a significant improvement in earnings per share versus that achieved in the year ended 31 December 2015 (19.7p).
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.